A5065678804- Estrogen and related hormone effects
- Breast Cancer Treatment Studies
- Cancer Risks and Factors
- Retinoids in leukemia and cellular processes
- Metabolism, Diabetes, and Cancer
- Cancer, Lipids, and Metabolism
- Growth Hormone and Insulin-like Growth Factors
- Prostate Cancer Treatment and Research
- Inflammatory mediators and NSAID effects
- Antioxidant Activity and Oxidative Stress
- Ovarian cancer diagnosis and treatment
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- BRCA gene mutations in cancer
- Advanced Breast Cancer Therapies
- Cancer-related Molecular Pathways
- Breast Lesions and Carcinomas
- Bladder and Urothelial Cancer Treatments
- Radiopharmaceutical Chemistry and Applications
- Hormonal and reproductive studies
- Pharmacogenetics and Drug Metabolism
- Endometrial and Cervical Cancer Treatments
- Colorectal Cancer Treatments and Studies
- Adipokines, Inflammation, and Metabolic Diseases
- Menopause: Health Impacts and Treatments
Ente Ospedaliero Ospedali Galliera
2016-2025
Queen Mary University of London
2015-2024
European Institute of Oncology
2012-2023
Istituti di Ricovero e Cura a Carattere Scientifico
2013-2023
Azienda Ospedaliero-Universitaria di Modena
2011-2019
National Hospital for Neurology and Neurosurgery
2019
University College London
2019
Princeton University
2018
Ospedale Policlinico San Martino
2016
University of Genoa
1987-2016
BACKGROUND: Fenretinide, a vitamin A analogue, has been shown to inhibit breast carcinogenesis in preclinical studies. We determined the efficacy of fenretinide preventing second malignancy women with cancer. METHODS: randomly assigned 2972 women, aged 30-70 years, surgically removed stage I cancer or ductal carcinoma situ receive for 5 years either orally (200 mg/day) no treatment. The primary end point was incidence contralateral ipsilateral 7 after randomization. Other points considered...
Metformin is associated with reduced breast cancer risk in observational studies patients diabetes, but clinical evidence for antitumor activity unclear. The change Ki-67 between pretreatment biopsy and post-treatment surgical specimen has prognostic value may predict cancer.After tumor biopsy, we randomly allocated 200 nondiabetic women operable to either metformin 850 mg/twice per day (n = 100) or placebo 100). primary outcome measure was the difference arms after 4 weeks adjusted baseline...
Tamoxifen administered for 5 years at 20 mg/d is effective in breast cancer treatment and prevention, but toxicity has limited its broad use. Biomarker trials showed that not inferior to decreasing proliferation. We hypothesized a lower dose given shorter period could be as preventing recurrence from intraepithelial neoplasia have than the standard dose.We conducted multicenter randomized trial of tamoxifen, or placebo 3 after surgery women with hormone-sensitive unknown neoplasia, including...
PURPOSE To update the ASCO guideline on pharmacologic interventions for breast cancer risk reduction and provide guidance clinical issues that arise when deciding to use endocrine therapy reduction. METHODS An Expert Panel conducted targeted systematic literature reviews identify new studies. RESULTS A randomized trial evaluated of anastrozole estrogen receptor–positive cancers in postmenopausal women at increased developing provided predominant basis update. UPDATED RECOMMENDATIONS In risk,...
Five-year data of the phase III trial TAM-01 showed that low-dose tamoxifen at 5 mg once daily administered for 3 years in women with intraepithelial neoplasia (IEN) reduced by 52% recurrence invasive breast cancer or ductal carcinoma situ (DCIS), without additional adverse events over placebo. Here, we present 10-year results.We randomly assigned 500 IEN (atypical hyperplasia, lobular [LCIS], hormone-sensitive unknown DCIS) to placebo after surgery irradiation. The primary end point was...
Initial findings of the Italian Randomized Tamoxifen Prevention Trial found no reduction in risk breast cancer with tamoxifen use, whereas National Surgical Adjuvant Breast and Bowel Project Cancer showed that treatment reduces estrogen receptor–positive cancer. Here we present an extended follow-up trial. From October 1, 1992, to December 31, 1997, 5408 otherwise healthy women who had undergone hysterectomy were randomly assigned a double-blind manner (20 mg daily) or placebo for 5 years....
<h3>Abstract</h3> <b>Objective</b> To assess the incidence, cofactors, and excess risk of development non-alcoholic fatty liver disease, including steatohepatitis, attributable to tamoxifen in women. <b>Design</b> Prospective, randomised, double blind, placebo controlled trial. <b>Setting participants</b> 5408 healthy women who had hysterectomies, recruited into Italian chemoprevention trial from 58 centres Italy. <b>Intervention</b> Women were randomly assigned receive (20 mg daily) or for...
Background: Tamoxifen reduces the risk of breast cancer in women at high for disease but increases endometrial tumors and venous thromboembolisms, possibly a dose-dependent fashion. We compared effects tamoxifen 1 mg/day 5 with those standard dose 20 on proliferation using surrogate endpoint marker (Ki-67 expression) blood biomarkers associated cancer, cardiovascular disease, bone fracture risk. Methods: randomly assigned 120 estrogen receptor (ER)-positive to 1, 5, or 4 weeks. Expression...
Abstract Purpose: Both therapeutic and adverse effects of tamoxifen may be related to its tissue concentrations. We investigated concentrations tamoxifen, 4-hydroxytamoxifen, N-desmethyltamoxifen, N-didesmethyltamoxifen in serum, normal breast, breast cancer tissues during conventional dosage two low-dose regimens. Furthermore we studied on the proliferation marker Ki-67, sex hormone-binding globulin (SHBG). Experimental Design: From September 1999 August 2001, 120 patients were randomized...
Several studies have identified an increased risk of cancer in type 2 diabetic patients and this is accordance with the hypothesis that insulin levels might promote cancer. Thus, there a great interest exploring possibility antidiabetic therapies lowering could decrease incidence or cancer-related mortality. Recent observational shown metformin, oral safe well-tolerated insulin-sensitizer drug, has been associated reduced risk. Recently, several preclinical evaluated effect metformin vivo on...
Screening with low-dose helical computed tomography (CT) has been shown to significantly reduce lung cancer mortality but the optimal target population and time interval subsequent screening are yet be defined. We developed two models stratify individual smokers according risk of developing cancer. first used number cancers detected at baseline CT in 5,203 asymptomatic participants COSMOS trial recalibrate Bach model, which we propose using select for screening. Next, incorporated nodule...